Reversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus: what can this teach us?
Von Feldt
Joan M
JM
D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D017277:Drug Approval; D006801:Humans; D020343:Hypertensive Encephalopathy / Q000139:chemically induced* / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D011358:Product Surveillance, Postmarketing; D012640:Seizures / Q000139:chemically induced* / Q000188:drug therapy; D013921:Thrombocytopenia / Q000188:drug therapy / Q000209:etiology
D007166:Immunosuppressive Agents; D016572:Cyclosporine